Vertiv Holdings Co vs Zimmer Biomet Holdings Inc — how do they compare? Vertiv Holdings Co trades at $285 (market cap $103.99B), while Zimmer Biomet Holdings Inc trades at $97.03 (market cap $18.65B). The key difference: Vertiv Holdings Co is far larger — about 5.6× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (0.98%). Which is the better fit depends on your goals.
| VRT | ZBH | |
|---|---|---|
Market Cap | $103.99B | $18.65B |
Sector | Technology | Health |
52-Week High | $376.23 | $107.71 |
52-Week Low | $121.82 | $79.58 |
Enterprise Value | $104.21B | $25.72B |
Dividend Yield | 0.09% | 0.98% |
Signals from Pluang's Aura AI — not financial advice
VRT trades at $272.40, down 1.01% on the day, with a bearish technical signal driven by moving averages and RSI levels near overbought territory. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.52 versus $1.43 expected, and revenue growth is supported by AI data center demand. Recent news highlights its role in AI infrastructure, though legal investigations pose a sentiment risk.
Outlook remains positive with a consensus price target of $386.58, reflecting 42% upside, driven by robust fundamentals and AI tailwinds. Risks include high valuation multiples, competitive pressures, and ongoing legal scrutiny. Investors should weigh growth potential against elevated P/E and market volatility.
Zimmer Biomet (ZBH) trades at $96.55, down 0.66% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.07, and raised its full-year outlook. Revenue growth remains steady, supported by hips, specialty businesses, and technology, though net income margin has moderated from 2023 peaks. Recent corporate news includes a dividend declaration and expansion of its technology center in India.
The outlook for ZBH is positive, driven by consistent earnings beats and strategic growth initiatives, but investors face risks from margin pressure and increasing debt levels. The stock offers potential upside to the consensus target, supported by institutional accumulation, though competitive and macroeconomic headwinds in the medtech sector warrant caution.
Trailing returns across standard periods
Latest headlines on both assets
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →